Resources
To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database
Results
showing 1-10 of 1031
The HIV Prevention Pipeline
This graphic shows currently available options for HIV prevention, newly approved and recommended treatment, and those in development.
Prevention Option:
ARV-Based and Multipurpose Prevention Technology R&D Pipeline
The pipeline of non-vaccine HIV prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals and more. Also pictured are the range of MPTs in development that aim to reduce the risk of HIV and STIs and/or provide effective contraception for women.
Prevention Option:
Years Ahead in HIV Prevention Research: Time to Market
This timeline shows the potential time points when the next-generation of HIV prevention options might find their way into new programs.
Prevention Option:
An “Innovation Pile-Up” in Next-Generation LA-PrEP is Possible
The HIV prevention market is headed toward a period of significant opportunity—and possible congestion—as a slate of new products are on track for continued development and potential introduction to the market in 2027 and 2028. Markets and policies must be built to support the products in the market already, so that new options can be rapidly deployed and deliver impact. Otherwise, the field will squander time and money, with epidemic control slipping further out of reach.
Prevention Option:
HIV Prevention Pipeline: Products to Watch
From the People’s Research Agenda, this graphic tracks the pipeline of potential new HIV prevention options across broadly neutralizing antibodies, preventive vaccines, pre-exposure prophylaxis, and multipurpose technologies.
Prevention Option:
People’s Research Agenda 2025 Update Summary Table
The People’s Research Agenda sets out a people-centered framework for equitable and accelerated R&D and product introduction. It tracks the science, shows where investments align—or fail to align—with community-defined priorities, and spotlights critical gaps in the pipeline of prevention options needed to meet the diverse realities of all populations.
Alimatravir (AMI) Licensing Timeline
This timeline demonstrates the speed of generic licensing for alimatravir (AMI) compared to lenacapavir (LEN) and cabotegravir (CAB).
Prevention Option:
INCLUSION Global Study Details
Gilead, Unitaid and the US National Institutes of Health are funding 36 ongoing studies to investigate implementation outcomes, rapid initiation and real-life use of injectable lenacapavir (LEN) for PrEP in 9 countries. Gilead’s INCLUSION program (INCLUSION Global in Africa and Asia and INCLUSION-US in the United States) accounts for 26 of these studies. This table provides details on the INCLUSION Global projects planned for 2026-2028 in 7 LEN early adopter countries.
Prevention Option:
Long-Acting PrEP Generic License Coverage
This map shows country coverage under current voluntary licensing agreements for generic versions of three long-acting PrEP products: alimatravir (AMI), cabotegravir (CAB) and lenacapavir (LEN). The graphic reflects publicly announced licenses and does not indicate product registration, availability or access within countries. For more information, visit the PrEPWatch Long-Acting PrEP Status page.
Prevention Option:
Accelerating policy approval and uptake of the dual prevention pill in Zambia through early stakeholder engagement
The Dual Prevention Pill (DPP), a combination of PrEP and combined oral contraception (COC), offers a novel, female-controlled option for HIV and unintended pregnancy prevention. This article in AIDS Care, authored by AVAC Fellow Rhoda Msiska, AVAC staff members Kate Segal and Cindra Feuer, and Newton Donkola, demonstrates how early, multisectoral stakeholder engagement could accelerate DPP approval and adoption in Zambia.
showing 1-10 of 1031